Li M, Pascual G, Glass C K
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla 92093-0651, USA.
Mol Cell Biol. 2000 Jul;20(13):4699-707. doi: 10.1128/MCB.20.13.4699-4707.2000.
The peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily that activates target gene transcription in a ligand-dependent manner. In addition, liganded PPARgamma can inhibit transcription of genes induced by gamma interferon (IFN-gamma) and/or lipopolysaccharides (LPSs), including the inducible nitric oxide synthase (iNOS) gene. Inhibition of the iNOS promoter is achieved partially through antagonizing the activities of NF-kappaB, AP-1, and STAT1, which are known to mediate effects of LPS and IFN-gamma. Previous studies have suggested that transrepression of these factors by nuclear receptors involves competition for limiting amounts of the general coactivators CREB-binding protein (CBP) and p300. CBP and p300 are thought to be recruited to nuclear receptors through bridging factors that include SRC-1, although CBP also interacts directly with PPARgamma through its amino terminus. These observations have raised questions concerning the involvement of SRC-1-like factors in CBP recruitment and transrepression. We here provide evidence that PPARgamma's ability to repress iNOS transcription requires the ligand-dependent charge clamp that mediates interactions with CBP and SRC-1. Single amino acid mutations in PPARgamma that abolished ligand-dependent interactions with SRC-1 and CBP not only resulted in complete loss of transactivation activity but also abolished transrepression. Conversely, a CBP deletion mutant containing the SRC-1 interaction domain but lacking the N-terminal PPARgamma interaction domain was inactive as a PPARgamma coactivator and failed to rescue transrepression. Together, these findings are consistent with a model in which transrepression by PPARgamma is achieved by targeting CBP through direct interaction with its N-terminal domain and via SRC-1-like bridge factors.
过氧化物酶体增殖物激活受体γ(PPARγ)是核受体超家族的成员,以配体依赖的方式激活靶基因转录。此外,与配体结合的PPARγ可抑制由γ干扰素(IFN-γ)和/或脂多糖(LPS)诱导的基因转录,包括诱导型一氧化氮合酶(iNOS)基因。对iNOS启动子的抑制部分是通过拮抗NF-κB、AP-1和STAT1的活性实现的,已知这些因子介导LPS和IFN-γ的作用。先前的研究表明,核受体对这些因子的反式抑制涉及对有限量的通用共激活因子CREB结合蛋白(CBP)和p300的竞争。CBP和p300被认为是通过包括SRC-1在内的桥接因子被招募到核受体上的,尽管CBP也通过其氨基末端直接与PPARγ相互作用。这些观察结果引发了关于SRC-1样因子在CBP招募和反式抑制中的作用的问题。我们在此提供证据表明,PPARγ抑制iNOS转录的能力需要介导与CBP和SRC-1相互作用的配体依赖性电荷钳。PPARγ中消除与SRC-1和CBP的配体依赖性相互作用的单个氨基酸突变不仅导致反式激活活性完全丧失,而且消除了反式抑制。相反,一个包含SRC-1相互作用结构域但缺乏N端PPARγ相互作用结构域的CBP缺失突变体作为PPARγ共激活因子无活性,并且未能挽救反式抑制。总之,这些发现与一个模型一致,即PPARγ的反式抑制是通过其N端结构域与CBP的直接相互作用以及通过SRC-1样桥接因子靶向CBP来实现的。